HC Wainwright & Co. Reiterates Buy on Krystal Biotech, Maintains $139 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Joseph Pantginis has reiterated a 'Buy' rating on Krystal Biotech (NASDAQ:KRYS) and maintained a price target of $139.
July 03, 2023 | 4:19 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Krystal Biotech's stock may see positive movement as HC Wainwright & Co. maintains a 'Buy' rating and a $139 price target.
Analyst ratings and price targets can significantly influence investor sentiment and stock price. The reiteration of a 'Buy' rating and a high price target by a reputable analyst like Joseph Pantginis from HC Wainwright & Co. is likely to boost investor confidence in Krystal Biotech, potentially leading to an increase in its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100